Sakar Healthcare Ltd · NSE:SAKAR
Sakar Healthcare — Investor Presentation (December 2018)
22 slides from Sakar Healthcare's investor presentation, Dec 12, 2018
Slide 1: Investor Presentation December 2018
Investor Presentation December 2018
Slide 2: Company Overview
Company Overview Engaged in manufacturing and marketing of diverse Operates as a Contract Manufacturer (CMO) range of pharmaceutical products: Oral Solids, Oral for leading Multinational Pharmaceutical Liquids, Liquid/lyophilized/dry powder injections. Companies. Manufactures formulations covering 2
Slide 3: Milestones
Milestones • Set up and commercialization of • Initial Public Offering of 14.81 Cr with Antibiotics and Injectable SVP Issue of 29,61,000 equity shares of Rs. plant. 10 each at issue price Rs. 50 per share. • Started Manufacturing of • Installed Lyophilizer and started formulations in form of tablet
Slide 4: Product Line
Product Line • This is the most widely used formulation type. The manufacturing process includes Oral Solids dispensing, sifting, granulation, drying, blending, compression, Tablet Coating/ capsule filling, packaging. • The liquid form is the most acceptable dosage form across age groups. It is norm
Slide 5: Business Model
Business Model Sakar: International Marketing • The company manufactures and markets its product through own distribution channels across Africa, Latin America, Asia and South East Asia and CIS countries. • Company has received necessary approvals from national drug authority of Kenya, Uganda, Yemen
Slide 6: Strengths
Strengths Experienced Management Team (Collective Domain Experience) Accreditation & World Wide State of Art Recognition Manufacturing Facility (WHO & Overseas Approvals) Strong Client Relationship (Over Modernised decades) Technology (lyophiliser) Wide Therapeutic Segment (22 Categories)
Slide 7: Experienced Promoter Team
Experienced Promoter Team.. MR. SANJAY SHAH MRS. RITA SHAH MR. AARSH SHAH FO U N D E R & D I R EC TO R J O I N T M A N AG I N G M A N AG I N G D I R EC TO R D I R EC TO R • Mr. Sanjay has more than a decade of experience in • Mrs. Rita Shah has been a Promoter Director of our • Mr. Aarash Shah curre
Slide 8: Strong Management Team
Strong Management Team MR. JOHNNEY GEORGE MR. SANJAY JAVIA Head Finance Plant Head – Oral Liquid Mr. George is with the organisation since inception and has ensured the systems and Mr.Sanjay Javia, is with the organisation since a decade. With a background in the processes are in place. His decade l
Slide 9: State of Art Manufacturing Facility
State of Art Manufacturing Facility • Manufacturing facility spread across 10,640 sq. m in Ahmedabad, Gujarat. • All four state of art manufacturing units are certified by WHO-GMP, cGMP and national drug authority of 14 overseas countries. Facility Product Manufactured Capacity (in lac units) Plant-
Slide 10: Modernised Technology
Modernised Technology Lyophilization State of The Art Equipment's • Toflon Make Lyophilizer • With automatic Loading & Unloading System • ORABs • Freeze Drying to improve Equipment make: solubility & stability of • Pam Glatt, Germany products • Brevetti, Italy • Bectochem • Cadmach (WHO approved)
Slide 11: Therapeutic Segment Coverage
Therapeutic Segment Coverage Antacid Antimalerial Anticoagulant Laxative Anthelmintic Bronchodilator Anaesthetic Adrenergic Antidepressant Sedative Anti-infective Therapeutic Segment Diuretics Oxytocic Analgesic Antipsychotic Antifungal Antiemetic PPI Anti-inflammatory Multi vitamins Anticonvulsant
Slide 12: Long Track Record With Clients
10 to 12 Years and Growing 8 to 10 Years and Growing 4 to 8 Years and Growing 1 to 4 Years and Growing Long Track Record With Clients
Slide 13: Certifications & Accreditations
Certifications & Accreditations Nigeria Uganda Vietnam Philippines Zimbabwe Peru Ghana Cote d’Ivorie Yemen Malawi Cambodia Kenya Ethiopia
Slide 14: World Wide Recognition
World Wide Recognition 69 distribution partners : 53 countries • Strong presence in South East Asia, Africa and Latin America. • Key Markets include Nigeria, Ethiopia, Kenya, Ghana, D.R Congo, Uganda, Cameroon, Philippines, Bolivia.
Slide 15: Industry Dynamics
Industry Dynamics Pharmaceutical Industry • India pharmaceutical industry is expected to expand at a CAGR of 22.4 per cent over 2015– 20 to reach US$ 55 billion. • India’s pharmaceutical exports stood at US$ 17.27 billion in 2017-18, In 2018-19 these exports are expected to cross US$ 19 billion. • I
Slide 16: Way Forward
Way Forward Enhancing Quality of Oncology Manufacturing Facilities Setting up a standalone manufacturing 01 facility for Oncology formulations & To widen the commercialization of freeze dried Active Pharmaceutical Ingredients products (capacity of 22,000 vials per batch of (API) which will help us v
Slide 17: Financial Highlights
Financial Highlights SALES BREAKUP GEOPRAPHICAL SALES 32% 45% 53% 49% 14% 22% 15% 19% 17% 18% 46% 36% 29% 34% 71% FY16 FY17 FY18 H1FY19 Direct Domestic Contract Export Africa Latin Amercia South East & Asian Countries
Slide 18: Financial Highlight
Financial Highlight REVENUE (In mn) DEBT TO EQUITY 530.7 0.99 412.2 441.7 271.5 0.58 0.21 0.1 FY16 FY17 FY18 H1FY19 FY16 FY17 FY18 H1FY19 EBIDTA (In mn) PAT (In mn) 125.8 38.1 33.7 31.6 101.6 83.4 69.6 22.1 11.6 7.2 20.2 23 23.7 26 5.4 7.6 FY16 FY17 FY18 H1FY19 FY16 FY17 FY18 H1FY19 EBIDTA EBIDTA (%
Slide 19: Profit & Loss
Profit & Loss Consolidated Financials (Rs. Lakhs) H1FY19 FY18 FY17 FY16 Total Income from Operations 2715.3 5307.65 4417.08 4122.6 Cost of Raw material Consumed 1391.5 2720.73 2281.95 2187.6 Changes in Inventory 15.36 79.19 -53.44 9.16 Total Raw material Consumed 1406.86 2799.92 2228.51 2196.76 Empl
Slide 20: Balance Sheet
Balance Sheet Rs. (Lakhs) H1FY19 FY18 FY17 FY16 Rs. (Lakhs) H1FY19 FY18 FY17 FY16 Equity Share Capital 1221 1221 1096 800 NON-CURRENT ASSETS 3777 3461 2454 1118 Reserve & Surplus 5738 5097 4893 3725 Property, Plant & Equipment 928 468 Money received against share warrants 225 236 5926 5150 3550 1918
Slide 21: Disclaimer
Disclaimer This presentation has been prepared by Sakar Healthcare Limited (the “Company”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any
Slide 22: Lets Connect!
Lets Connect! CIN: L24231GJ2004PLC043861 KDA Strategic Advisors Contact: Helpdesk Contact: Mr. Sagar Mehta/ Mr. Vivek Jain +91-79-26584655 +91-9892122787/+91-8928791740 Email Id: info@sakarhealthcare.com Email Id: sagarm@kdg.co.in/vivekj@kdg.co.in
Sakar Healthcare — Investor Presentation (December 2018) on 6ix